Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225475 | 0.82 | KMO (0.38) | KMOHTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL1744668 | 0.80 | CTNNB1 (0.34) | — | |
| SCHEMBL1744851 | 0.72 | ACACB (0.35) | KMOHTR2AHTR2C | |
| SCHEMBL3343371 | 0.71 | HTR2A (0.39) | KMOHTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL15516226 | 0.70 | HTR2A (0.38) | KMOHTR2AHTR2CHTR2BP2RX7 | |
| SCHEMBL13607689 | 0.69 | KMO (0.52) | KMOHTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL3343370 | 0.68 | CCNA2 (0.34) | — | |
| SCHEMBL20719072 | 0.67 | NOTUM (0.35) | KMOHTR2AHTR2C | |
| SCHEMBL3482763 | 0.67 | CYP1A2 (0.45) | KMOHTR2AHTR2CHTR2BNR3C1 | |
| SCHEMBL14578727 | 0.67 | KMO (0.47) | KMOHTR2AHTR2CHTR2BNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | claimed |
| US-8372865-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2385939-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8041551-B1 | Algorithm and architecture for multi-argument associative operations that minimizes the number of components using a latency of the components | THE MATHWORKS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010072597-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160373-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX3, P2RX1 | KMO 2960/4885HTR2A 193/4885HTR2C 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.